Compare LPTH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | NBTX |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2011 | 2018 |
| Metric | LPTH | NBTX |
|---|---|---|
| Price | $15.62 | $35.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $13.33 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 4.0M | 65.3K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $83.04 | $58.17 |
| Revenue Next Year | $24.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $2.75 | $4.29 |
| 52 Week High | $18.94 | $57.14 |
| Indicator | LPTH | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 39.26 |
| Support Level | $10.25 | $29.64 |
| Resistance Level | $15.89 | $34.66 |
| Average True Range (ATR) | 1.72 | 2.68 |
| MACD | 0.17 | -1.62 |
| Stochastic Oscillator | 59.34 | 0.00 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.